Genmab A/S (GMAB) Posts 75%/67% ORRs in Phase 2 mCRC, Backs Phase 3

Genmab reported Phase 2 trial results for petosemtamab in mCRC, showing 75% ORR in first-line and 67% in second-line patients. The data support ongoing global Phase 3 trials, according to the company.

Original reporting
Published Oct 25, 2026, 11:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 25, 2026, 11:10 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Genmab A/S (GMAB) Posts 75%/67% ORRs in Phase 2 mCRC, Backs Phase 3 — source image
Decision brief

The 30-second read

$GMABBullishMed
01

Why it matters

The data could accelerate partnership talks and increase valuation multiples for similar biotech assets.

02

Market read

First report of robust Phase 2 efficacy for a late‑stage oncology candidate, likely to influence biotech sector sentiment.

03

What to watch

Potential safety signals or trial enrollment challenges could temper enthusiasm despite high ORR.

Relevance 8/10Novelty 8/10Timing: today

Background

Genmab is expanding its oncology portfolio beyond hematology, targeting colorectal cancer with petosemtamab combined with standard chemotherapy.

Company-level read

Ticker impact

$GMABBullishHigh confidence
Context

Genmab disclosed Phase 2 trial results showing 75% ORR in 1L mCRC and 67% in 2L, a new efficacy signal.

Expected impact

likely upside as market prices in the positive efficacy data

Evidence & confidence

Efficacy rates are markedly high for mCRC, reducing risk perception and prompting buying interest.

Market effects

Boosts confidence in biotech firms developing antibody‑drug conjugates for solid tumors.

May lift European biotech indices where Genmab is a component.

Adds to broader optimism in oncology pipeline developments.

Counterpoint

Investors may question durability of response rates and await Phase 3 confirmation before committing.

Key entities

  • Genmab A/S

    Danish biotech developing antibody‑drug conjugates.

Related articles

$GMABHighAI 8/10

Genmab (GMAB) Q3 2026 Earnings Call Transcript

Genmab reported positive phase III trial results for Epkinly, Rina-S, and petosemtamab, with Epkinly showing a hazard ratio of 0.49 in the EPCORE DLBCL-2 trial. Sales for Epkinly and Tivdak grew 47% and 9% year-over-year, respectively, to $491M and $131M in the first nine months of 2026. The company is preparing for potential launches in early lines of DLBCL and other indications.

$GMABMedAI 8/10

Why is Genmab stock sliding today?

Genmab (GMAB) shares fell 4.9% after Q3 revenue of $1.19B missed estimates, though EPS beat. Epkinly sales grew 47% but lagged Jyske Bank's forecast. Full-year guidance remained unchanged, disappointing some analysts. Higher costs reduced net profit. The company maintained its revenue and earnings outlook but did not raise it, despite recent clinical trial successes.